Fred Hassan

Fred Hassan "joined Warburg Pincus in 2009 as a Senior Advisor and focuses on the firm’s healthcare investment activities. Mr. Hassan served as chairman and CEO of Schering-Plough Corporation from 2003 until its acquisition by Merck & Co., Inc. on November 3, 2009. Before joining Schering-Plough, he served as chairman and CEO of Pharmacia Corporation until the company was acquired by Pfizer Inc. in 2003. From 1997 to 2000, Mr. Hassan was CEO of Pharmacia & Upjohn, Inc., which merged with Monsanto Company in 2000 to become Pharmacia Corporation. From 1972 to 1997, he served in various senior management roles at major pharmaceutical companies. Mr. Hassan recently joined the Board of Directors of Bausch & Lomb and Time Warner Inc. He is also the lead director on the Board of Avon Products, Inc., where he has served since 1999. At Warburg Pincus, he advises the Healthcare Group and provides strategic counsel across the firm's portfolio. Mr. Hassan received his B.S. from the Imperial College of Science and Technology at the University of London and an M.B.A. from Harvard Business School."

Mr. Hassan has served as a Board member of Intrexon "since June 2016. Mr. Hassan joined Warburg Pincus LLC, a global private equity investment institution, in 2010 and currently serves as Director. Previously, Mr. Hassan served as Chairman and Chief Executive Officer of Schering-Plough from 2003 to 2009. Before assuming these roles, from 2001 to 2003, Mr. Hassan was Chairman and Chief Executive Officer of Pharmacia Corporation, a company formed as a result of the merger of Monsanto Company and Pharmacia & Upjohn, Inc. He joined Pharmacia & Upjohn, Inc. as Chief Executive Officer in 1997. Mr. Hassan previously held leadership positions with Wyeth serving as Executive Vice President, and was a member of the board from 1995 to 1997. Earlier in his career, he spent a significant tenure with Sandoz Pharmaceuticals and headed the company’s U.S. pharmaceuticals business.

"Since July 2015, Mr. Hassan has served as a director of Amgen, Inc. (Nasdaq: AMGN), a leading biotechnology company. Mr. Hassan served as a director of Time Warner Inc. (now Warner Media, LLC), a global leader in media and entertainment, from October 2009 to June 2018. In the course of his career, he has held numerous directorships, including those at Avon Products, Inc. from 1999 to 2013, Bausch & Lomb from 2010 until its acquisition by Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (“Valeant”) in 2013, and Valeant from 2013 to 2014. Mr. Hassan has chaired notable pharmaceutical industry organizations including The Pharmaceutical Research and Manufacturers of America (PhRMA) and The International Federation of Pharmaceutical Manufacturers Associations (IFPMA) and is also a member of The Business Council. Mr. Hassan received a B.S. degree in chemical engineering from the Imperial College of Science and Technology at the University of London and an M.B.A. from Harvard Business School."

Resources and articles

Related Sourcewatch

• Stephen Evans-Freke - former advisor